MGUS/MM Awareness and Genetics Insights Campaign (MAGIC) Screening Study

NCT06472830 | Enrolling By Invitation

• 1 other identifier: 23-008956
• Study Type: observational
• Target: 1,000
• Locations: 1 country
• Sites: 1

Brief Summary

This study is being done to screen adults for MGUS and to better understand the genetic and immune factors linked to this condition. Monoclonal gammopathy of undetermined significance or MGUS is a condition where an abnormal immune protein is found in the blood. MGUS is not cancer. In some people, it slowly develops into a blood cancer called multiple myeloma. MGUS occurs in people from all backgrounds. Researchers hope to use the information from this study to improve knowledge, early detection, and future care for everyone.

Conditions

Monoclonal Gammopathy of Undetermined Significance

Outcome Measures

Primary Outcomes (1)

• Prevalence of monoclonal gammopathies across ancestrally diverse populations

  Screen for monoclonal gammopathies using mass spectrometry to detect monoclonal proteins among people across ancestrally diverse populations in Minnesota, with prespecified, ancestry-informed analyses within East African, West African, Afro-Caribbean, and Non-Hispanic White groups.

  Up to 10 years

Study Arms (1)

Observational

Participants undergo medical chart review and blood sample collection, as well as complete a questionnaire on study. Participants who test positive for MGUS are notified, along with their primary care physician, so that the necessary follow up and referral is provided as clinically indicated.

Other: Non-Interventional Study

Interventions

Non-Interventional Study OTHER

Non-interventional study

Observational

Eligibility Criteria

• Age: 40 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adults attending primary care clinics at Mayo Clinic and Mayo Clinic Health Systems, or health fairs and events

You may qualify if:

• Adults ≥ 40 years
• Willing and able to review, understand, and provide consent before starting any study-specific procedures
• Ability to complete questionnaire(s) by themselves or with assistance

You may not qualify if:

• Pregnant women

Sponsors & Collaborators

• Mayo Clinic: lead

Study Sites (1)

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

Location

Related Links

• Mayo Clinic Clinical Trials

Biospecimen

Retention: SAMPLES WITH DNA

Blood

MeSH Terms

Conditions

Monoclonal Gammopathy of Undetermined Significance

Condition Hierarchy (Ancestors)

Hypergammaglobulinemia; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Paraproteinemias; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Joselle M. Cook, M.B.B.S.

  Mayo Clinic in Rochester

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 19, 2024
• First Posted: June 25, 2024
• Study Start: May 22, 2024
• Primary Completion (Estimated): May 31, 2029
• Study Completion (Estimated): May 31, 2029
• Last Updated: March 30, 2026

Record last verified: 2026-03

Locations

US (1)